Tuesday, 9 November 2021 to Wednesday, 10 November 2021
| Getting started with high-throughput mass spectrometry in early drug discovery | |||||
|
Wed10 Nov11:00am(30 mins)
|
|
Dr Martin Bachman | |||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Assist Plus | |||||
|
Tue9 Nov11:45am(5 mins)
|
|
|
Ms Sharon Barnard | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Using DiBT-MS for high throughput and novel biocatalyst pharmaceutical discovery | |||||
|
Wed10 Nov09:10am(50 mins)
|
|
|
Perdita Barran | ||
|
Session : Keynote Presentation
Room: Auditorium
|
|||||
| Pragmatic screening collection refinement to facilitate hit progression | |||||
|
Tue9 Nov04:05pm(30 mins)
|
|
|
Dr Kristian Birchall | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Reactive fragment screening for expansion of the liganded proteome | |||||
|
Wed10 Nov02:00pm(30 mins)
|
|
|
Jacob Bush | ||
|
Room: Helix Room
|
|||||
| Case studies in cellular nuisance compounds | |||||
|
Tue9 Nov11:50am(30 mins)
|
|
|
Dr Jayme Dahlin | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Right assay, right hit, right time. Identify “more physiological hits” earlier in drug discovery | |||||
|
Tue9 Nov03:35pm(30 mins)
|
|
Mrs Kathy Dodgson | |||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Patient-derived cell models as a clinically-relevant drug discovery strategy | |||||
|
Tue9 Nov04:05pm(30 mins)
|
|
|
Gareth Griffiths | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Building a high-throughput MS workflow for covalent Hit Finding | |||||
|
Wed10 Nov10:30am(30 mins)
|
|
Dr Sarah Hewitt | |||
|
Room: Helix Room
|
|||||
| New way of screening: A case study comparing an iterative screening approach to conventional HTS campaigns. | |||||
|
Wed10 Nov02:00pm(30 mins)
|
|
|
Markus Hierl | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| CDD Vault - Complexity Simplified | |||||
|
Tue9 Nov02:30pm(5 mins)
|
|
|
Miss Tamsin Lamont | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Computational and Empirical Strategies to Triage Nuisance Compounds in HTS | |||||
|
Tue9 Nov02:35pm(30 mins)
|
|
Scott Maidment | |||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| An Introduction of the Medicines Discovery Catapult | |||||
|
Tue9 Nov02:30pm(5 mins)
|
|
|
Dr Martin Main | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Bioluminescent Tools & Approaches for RAS Pathway Drug Discovery | |||||
|
Tue9 Nov10:15am(15 mins)
|
|
|
Dr Craig Malcolm | ||
|
Session : Keynote Presentation
Room: Auditorium
|
|||||
| An update on the JUMP-CP Consortium: insights from pilot experiments and outlook | |||||
|
Tue9 Nov11:15am(30 mins)
|
|
|
Paula A. Marin-Zapata | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Computational and Empirical Strategies to Triage Nuisance Compounds in HTS | |||||
|
Tue9 Nov02:35pm(30 mins)
|
|
Sarah Martin | |||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Developing assay development tools to make screening less PAINS-full | |||||
|
Tue9 Nov02:00pm(30 mins)
|
|
|
Dr Stuart McElroy | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| Application of Acoustic Mist Ionisation MS to rapidly identify hits with undesirable mechanisms of action in HTS outputs | |||||
|
Tue9 Nov11:15am(30 mins)
|
|
|
Dr Rachel Moore | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| The concept of G-quadruplex ligands as novel gene regulators and potential anticancer drugs | |||||
|
Tue9 Nov02:35pm(30 mins)
|
|
|
Stephen Neidle | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Identification of allosteric binders of an active GPCR : Screening of EDELRIS Keymical Space™ by Affinity Selection-Mass Spectrometry | |||||
|
Wed10 Nov02:30pm(30 mins)
|
|
|
Mr Renaud Prudent | ||
|
Room: Helix Room
|
|||||
| Modernising Drug Design and Prioritisation with AI | |||||
|
Wed10 Nov10:30am(30 mins)
|
|
Simon Richards | |||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| MALDI-TOF AS-MS – a label-free hit validation strategy in early drug discovery | |||||
|
Wed10 Nov11:15am(15 mins)
|
|
|
Dr Roman Simon | ||
|
Room: Helix Room
|
|||||
| R&D at the New Speed of Science - Accelerate your R&D Transformation with Benchling | |||||
|
Tue9 Nov11:45am(5 mins)
|
|
Jonathan Stone | |||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Hit or Miss? The Importance of Triage in the Active to Hit Transition | |||||
|
Tue9 Nov03:35pm(30 mins)
|
|
|
Alexandra Stowell | ||
|
Session : Hit Triage
Room: Helix Room
|
|||||
| A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia | |||||
|
Wed10 Nov02:30pm(30 mins)
|
|
|
Prof Matthias Trost | ||
|
Session : Emerging Discovery Strategies
Room: Auditorium
|
|||||
| Revolutionizing Screening: MALDI-ToF Mass Spectrometry in a Fully Automated HTS System | |||||
|
Wed10 Nov01:30pm(30 mins)
|
|
|
Dr Steven van Helden | ||
|
Room: Helix Room
|
|||||
| Utilizing biophysics to kick start drug discovery projects | |||||
|
Wed10 Nov11:00am(15 mins)
|
|
|
Dr Jana Wolf | ||
|
Room: Helix Room
|
|||||
